UK pricing body set to shake up appraisal methods

19 August 2021

In the UK, drug developers and other stakeholders have until October 13, 2021 to provide input on proposed changes to the health technology assessment (HTA) methods used by the country’s HTA body.

The National Institute for Health and Care Excellence (NICE) has undertaken perhaps the most wide-ranging and thorough review of its processes in its history, involving partners, patients and healthcare professionals as well as representatives from industry and academia.

The group wants to respond to technological advances in medicines and data, while ensuring predictability, transparency and efficiency of decision-making.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK